Bart Nijmeijer

1.0k citations

36 papers · 757 indexed · h-index 16

Molecular Biology
Oncology top 10%
Hematology top 5%
Genetics top 10%
Public Health, Environmental and Occupational Health

Co-authors: J.H. Frederik Falkenburg Roel Willemze Inge Jedema Harald Petry Martin de Haan Marianke L.J. van Schie Renée M. Y. Barge Vincent H. J. van der Velden
Topics: CAR-T cell therapy research (10 papers)Acute Lymphoblastic Leukemia research (9 papers)Virus-based gene therapy research (8 papers)
Cited by: Hematology Oncology Genetics
Journals: Angewandte Chemie International Edition Blood PLoS ONE
Partner nations: Netherlands Germany United States

In The Last Decade

Bart Nijmeijer

36 papers receiving 741 citations

Peers

Countries citing papers authored by Bart Nijmeijer

Since Specialization

Citations

This map shows the geographic impact of Bart Nijmeijer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Nijmeijer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Nijmeijer more than expected).

Fields of papers citing papers by Bart Nijmeijer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Nijmeijer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Nijmeijer. The network helps show where Bart Nijmeijer may publish in the future.

Co-authorship network of co-authors of Bart Nijmeijer

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Nijmeijer. A scholar is included among the top collaborators of Bart Nijmeijer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Nijmeijer. Bart Nijmeijer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells 2023 ·PLoS ONE ·(unknown),Sandra Torres,Cristina Ortiz,Robert Schierwagen,Olaf Tyc,(unknown),Marie‐Luise Berres,(unknown),(unknown),Stefan Zeuzem,Bart Nijmeijer,(unknown),Jonel Trebicka,Sabine Klein	7
2	Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice 2023 ·JHEP Reports ·(unknown),(unknown),(unknown),Bart Nijmeijer,Ulrich Beuers,Ronald P.J. Oude Elferink,Stan F.J. van de Graaf	7
3	Titelbild: An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt^II Linker Lx for Improved Manufacturability of Antibody–Drug Conjugates (Angew. Chem. 6/2021) 2021 ·Angewandte Chemie ·Eugen Merkul,(unknown),(unknown),(unknown),Bart Nijmeijer,(unknown),J. Reedijk,Guus A.M.S. van Dongen	1
4	An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt^IILinkerLxfor Improved Manufacturability of Antibody–Drug Conjugates 2020 ·Angewandte Chemie ·Eugen Merkul,(unknown),(unknown),(unknown),Bart Nijmeijer,(unknown),J. Reedijk,Guus A.M.S. van Dongen	1
5	An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt^IILinkerLxfor Improved Manufacturability of Antibody–Drug Conjugates 2020 ·Angewandte Chemie International Edition ·Eugen Merkul,(unknown),(unknown),(unknown),Bart Nijmeijer,(unknown),J. Reedijk,Guus A.M.S. van Dongen	15
6	First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs) 2019 ·Expert Opinion on Drug Delivery ·Eugen Merkul,(unknown),(unknown),(unknown),(unknown),(unknown),Bart Nijmeijer,Guus A.M.S. van Dongen	16
7	Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs 2019 ·Molecular Therapy — Methods & Clinical Development ·(unknown),Bart Nijmeijer,Margit H. Lampen,(unknown),Martin de Haan,Harald Petry,S J van Deventer,Christian Niels Meyer,Marco J.D. Tangelder,Valérie Ferreira	92
8	Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs 2019 ·Molecular Therapy — Methods & Clinical Development ·(unknown),Ying Poi Liu,Jacek Lubelski,Erich Ehlert,(unknown),(unknown),Martin de Haan,Bart Nijmeijer,Valérie Ferreira,Harald Petry,S J van Deventer	25
9	Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system 2018 ·Gene Therapy ·(unknown),(unknown),Erich Ehlert,Bart Nijmeijer,Martin de Haan,Harald Petry,Jacek Lubelski	43
10	Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia 2013 ·PLoS ONE ·(unknown),(unknown),Roman Pfeifer,(unknown),Bart Nijmeijer,(unknown),J.H. Frederik Falkenburg,Martin Ruthardt,Oliver G. Ottmann	53
11	Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model 2011 ·Leukemia Research ·Beate Schultheis,Bart Nijmeijer,Hua Yin,Roger G. Gosden,Junia V. Melo	47
12	Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors 2009 ·Experimental Hematology ·Bart Nijmeijer,Károly Szuhai,Henriëtte M. Goselink,Marianke L.J. van Schie,(unknown),Daniëlle de Jong,Erik W.A. Marijt,Oliver G. Ottmann,Roel Willemze,J.H. Frederik Falkenburg	52
13	Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement 2008 ·Cancer Genetics and Cytogenetics ·(unknown),Károly Szuhai,J.H. Frederik Falkenburg,Marianke L.J. van Schie,Oliver G. Ottmann,Bart Nijmeijer	15
14	Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia 2007 ·Leukemia Research ·Kirsten J. M. Schimmel,Bart Nijmeijer,Marianke L.J. van Schie,J.H. Frederik Falkenburg,Henk‐Jan Guchelaar	1
15	Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria 2006 ·APOPTOSIS ·Jeltje F. de Vries,Linda J. Wammes,Inge Jedema,(unknown),Bart Nijmeijer,Mirjam H.M. Heemskerk,Roel Willemze,JH Falkenburg,Renée M. Y. Barge	19
16	Upregulation of CD20 on Human Acute Lymphoblastic Leukemia Cells by IL-4 and CpG Motif Containing Oligonucleotides Increases Susceptibility to Rituximab. 2006 ·Blood ·Bart Nijmeijer,Marianke L.J. van Schie,R. Willemze,J.H. Frederik Falkenburg	1
17	Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia 2005 ·Experimental Hematology ·Bart Nijmeijer,Marianke L.J. van Schie,(unknown),Roel Willemze,J.H. Frederik Falkenburg	7
18	Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity 2003 ·Leukemia ·Inge Jedema,Renée M. Y. Barge,Vincent H. J. van der Velden,Bart Nijmeijer,Jacques J. M. van Dongen,Roel Willemze,J.H. Frederik Falkenburg	111
19	Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice 2001 ·Experimental Hematology ·Bart Nijmeijer,P. Mollevanger,Shama L. van Zelderen‐Bhola,Hanneke C. Kluin‐Nelemans,(unknown),JH Falkenburg	42
20	The mechanism of N-acetylcysteine photoprotection is not related to dipyrimidine photoproducts 1998 ·Journal of Photochemistry and Photobiology B Biology ·Bart Nijmeijer,David P. T. Steenvoorden,G. M. J. Beijersbergen van Henegouwen,(unknown),Arie A. Vink	8

About Bart Nijmeijer

Bart Nijmeijer is a scholar working on Hematology, Genetics and Oncology, having authored 36 papers that have together received 757 indexed citations. Recurring topics across this work include CAR-T cell therapy research (10 papers), Acute Lymphoblastic Leukemia research (9 papers) and Virus-based gene therapy research (8 papers). The work is most often cited by research in Hematology (249 citations), Oncology (287 citations) and Genetics (77 citations). Bart Nijmeijer has collaborated with scholars based in Netherlands, Germany and United States. Frequent co-authors include J.H. Frederik Falkenburg, Roel Willemze, Inge Jedema, Harald Petry, Martin de Haan, Marianke L.J. van Schie, Renée M. Y. Barge, Vincent H. J. van der Velden, Jacques J. M. van Dongen and Oliver G. Ottmann. Their work appears in journals such as Angewandte Chemie International Edition, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact